Absci Corporation (NASDAQ: ABSI) and Invetx revealed a strategic collaboration to develop a Half-Life Extension (HLE) platform for animal health applications using Absci’s generative AI Drug Creation models, as per a press release. This partnership aims to enhance the therapeutic landscape for companion animals by leveraging advanced AI technology.
Absci CEO Sean McClain underlined the company’s expertise in generative AI for therapeutic antibodies, saying they were excited to bring this expertise into animal health and work with Invetx to advance care in veterinary medicine. Under the agreement, Absci will design modular antibody sequences to extend therapeutic duration in specific animal species. Invetx will gain rights to integrate this HLE platform into multiple products, offering improved therapeutic effects and customer convenience.
The partnership includes R&D funding, election fees, milestone payments, and per-product royalties, reflecting the significant market potential. Invetx President Juergen Horn noted that collaborating with Absci, they aim to build a scalable platform for innovative animal therapeutics, leveraging Absci’s expertise in generative AI.
The collaboration targets unmet needs in animal health, starting with large-market canine applications and potentially expanding to other companion animals.
Absci, headquartered in Vancouver, WA, specializes in integrating AI and wet lab technologies to accelerate biologic drug creation. Invetx, based in Boston, focuses on developing protein-based therapeutics for veterinary care and was acquired by Dechra Pharmaceuticals in 2024. Together, the companies aim to bring advanced therapeutic solutions to the underserved animal health sector.
